
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is a clinical-stage biotechnology company developing anti-inflammatory therapeutics targeting C5a/C5aR complement pathway. With its lead candidate, izicopan, expected to effectively replace the now impaired Tavneos (avacopan) as the standard-of-care in ANCA-associated vasculitis, and promising data for other indications, the company has a strong pipeline. Additionally, with Gohibic (vilobelimab) already approved for emergency/exceptional treatment of COVID, InflaRx has the potential for near-term revenue generation.
Bears say
InflaRx is facing significant challenges in the development of their product candidates, as proven by the multiple indications still being studied in proof of concept trials. Furthermore, the proposed Phase 3 trial for their candidate, izicopan, may change its primary endpoints based on Phase 2 data and interactions with the FDA. In addition, potential hepatotoxicity and concerns about the drug's efficacy in treating autoimmune diseases raise concerns about its commercial potential. With these uncertainties and risks, the financial outlook for InflaRx appears negative.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares